Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2019

Schedule of Accounting for Stock-Based Compensation

The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and recorded in connection with stock options granted to non-employee consultants:


	Six Months Ended
	June 30,
	2019		2018

Employee and director stock option grants:
Research and development	$	26,003	$	70,752
General and administrative		483,122		278,265
Total stock-based compensation	$	509,125	$	349,017

Schedule of Stock Options Activity

A summary of stock option activity is as follows:


				Weighted
	Number of			Average
	Shares Issuable			Remaining
	Upon Exercise	Weighted		Contracted	Aggregate
	of Outstanding	Average		Term in	Intrinsic
	Options	Exercise Price		Years	Value
Outstanding at December 31, 2018	232,343	$	14.37		$
Granted	321,930	$	2.33
Expired	—	$	—
Forfeited	(33,559)	$	4.78
Outstanding at June 30, 2019	520,714	$	7.55

Exercisable, June 30, 2019	117,709	$	24.83	8.39	$	—
Unvested, June 30, 2019	403,005	$	2.50	9.43	$	23,635

Schedule of Restricted Stock Grants

The following table summarizes the restricted stock grants:


		Weighted
		Average
		Grant Date		Total Grant
	Number of	Fair Value		Date Fair
	Shares	Per Share		Value
Outstanding at December 31, 2018	18,668	$	21.00	$	392,000
Granted	—	$	—	$	—
Vested	(9,334)	$	21.00	$	(196,000)
Forfeited	—	$	—	$	—
Outstanding at June 30, 2019	9,334	$	21.00	$	196,000